[A20-12] Elotuzumab (multiple myeloma) - Addendum to Commission A19-80
Last updated 02.04.2020
Commission awarded on 10.03.2020 by the Federal Joint Committee (G-BA).
Adult patients with relapsed and refractory multiple myeloma after at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on the last therapy
Conclusion of dossier assessment A19-80 unchanged: indication of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.